CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Faron is developing CLEVEGEN, an innovative cancer treatment that targets a molecule called Clever-1 on tumor-associated macrophages. This immunotherapy aims to enhance the body's immune response against cancer, showing promising results in early clinical trials for difficult-to-treat cancer types.
Cancer is a leading cause of death in the world despite relentless research to discover new treatments.
There were over 18M new cancer cases and 9.6M deaths due to cancer worldwide in 2018.
Human suffering due to cancer is devastating.
The impact and cost of cancer to society is extensive and complex.
Faron aims to provide a new solution that could replace several currently used ineffective cancer treatments.
Faron is a Finnish biotech company committed to high-quality R&D to fulfil the company’…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
